View Older Stories View More Recent Stories

Oct 23, 2022 12:01PM Phathom Pharmaceuticals Presents New Data Evaluating First-in-Class Potassium-Competitive Acid Blocker (PCAB) Vonoprazan as Novel On-Demand Treatment in NERD at American College of Gastroenterology (A
Oct 18, 2022 08:00AM Phathom Pharmaceuticals to Present Latest Data on Vonoprazan at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting
Oct 18, 2022 08:00AM Phathom Pharmaceuticals to Present Latest Data on Vonoprazan at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting
Sep 26, 2022 08:00AM Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors
Sep 26, 2022 08:00AM Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors
Sep 7, 2022 08:15AM Phathom Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Sep 7, 2022 08:15AM Phathom Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Aug 2, 2022 08:00AM Phathom Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Updates
Aug 2, 2022 08:00AM Phathom Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Updates
Jun 1, 2022 08:15AM Phathom Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference
Jun 1, 2022 08:15AM Phathom Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference
May 25, 2022 08:06AM Phathom Pharmaceuticals Inc. (PHAT) Announces FDA Acceptance for Filing of Vonoprazan NDA for the Treatment of Erosive Esophagitis
May 25, 2022 08:00AM Phathom Pharmaceuticals Announces FDA Acceptance for Filing of Vonoprazan NDA for the Treatment of Erosive Esophagitis
May 25, 2022 08:00AM Phathom Pharmaceuticals Announces FDA Acceptance for Filing of Vonoprazan NDA for the Treatment of Erosive Esophagitis
May 24, 2022 12:15PM Phathom Pharmaceuticals Presents Data on Novel Potassium-Competitive Acid Blocker (PCAB) Vonoprazan from a Range of Studies at Digestive Disease Week® (DDW) 2022
May 24, 2022 12:15PM Phathom Pharmaceuticals Presents Data on Novel Potassium-Competitive Acid Blocker (PCAB) Vonoprazan from a Range of Studies at Digestive Disease Week® (DDW) 2022
May 17, 2022 08:01AM Phathom Pharmaceuticals to Present Data at DDW 2022 Annual Meeting
May 17, 2022 08:01AM Phathom Pharmaceuticals to Present Data at DDW 2022 Annual Meeting
May 10, 2022 08:00AM Phathom Pharmaceuticals Reports First Quarter 2022 Results and Provides Recent Clinical, Regulatory, and Business Updates
May 10, 2022 08:00AM Phathom Pharmaceuticals Reports First Quarter 2022 Results and Provides Recent Clinical, Regulatory, and Business Updates
May 4, 2022 08:01AM Phathom Pharmaceuticals Inc. (PHAT) Enters Non-Dilutive Revenue Interest Financing Agreement for Up to $260M
May 4, 2022 08:01AM Phathom Pharmaceuticals Announces Revenue Interest Financing Agreement for Up to $260 Million in Non-Dilutive Capital
May 4, 2022 08:01AM Phathom Pharmaceuticals Announces Revenue Interest Financing Agreement for Up to $260 Million in Non-Dilutive Capital
May 3, 2022 05:41PM Phathom Pharmaceuticals (PHAT) Announces FDA Approval of VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK for the Treatment of H. pylori Infection in Adults
May 3, 2022 05:40PM Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for the Treatment of H. pylo
May 3, 2022 05:40PM Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for the Treatment of H. pylo
Apr 26, 2022 08:03AM Phathom Pharmaceuticals (PHAT) Appoints Frank Karbe to its Board of Directors
Apr 26, 2022 08:00AM Phathom Pharmaceuticals Appoints Frank Karbe to its Board of Directors
Apr 26, 2022 08:00AM Phathom Pharmaceuticals Appoints Frank Karbe to its Board of Directors
Apr 1, 2022 08:01AM Phathom Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference
Apr 1, 2022 08:01AM Phathom Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference
Mar 22, 2022 08:03AM Phathom Pharmaceuticals Inc. (PHAT) Appoints Molly Henderson as Chief Financial and Business Officer
Mar 22, 2022 08:02AM Phathom Pharmaceuticals Announces Appointment of Molly Henderson as Chief Financial and Business Officer
Mar 22, 2022 08:02AM Phathom Pharmaceuticals Announces Appointment of Molly Henderson as Chief Financial and Business Officer
Mar 14, 2022 08:03AM Phathom Pharmaceuticals Inc. (PHAT) Submits Vonoprazan NDA to FDA for the Treatment of Erosive Esophagitis
Mar 14, 2022 08:02AM Phathom Pharmaceuticals Submits Vonoprazan NDA to FDA for the Treatment of Erosive Esophagitis
Mar 14, 2022 08:02AM Phathom Pharmaceuticals Submits Vonoprazan NDA to FDA for the Treatment of Erosive Esophagitis
Mar 1, 2022 04:04PM Phathom Pharmaceuticals Inc. (PHAT) Reports Q4, Highlights Recent Pipeline and Business Progress
Mar 1, 2022 04:04PM Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Pipeline and Business Progress
Mar 1, 2022 04:04PM Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Pipeline and Business Progress
Feb 9, 2022 04:04PM Phathom Pharmaceuticals Inc. (PHAT) Reports Positive Topline Results from Phase 2 Trial Evaluating Vonoprazan
Feb 9, 2022 04:04PM Phathom Pharmaceuticals Announces Positive Topline Results from Phase 2 Trial Evaluating Vonoprazan for Non-Erosive Gastroesophageal Reflux Disease (NERD)
Feb 9, 2022 04:04PM Phathom Pharmaceuticals Announces Positive Topline Results from Phase 2 Trial Evaluating Vonoprazan for Non-Erosive Gastroesophageal Reflux Disease (NERD)
Nov 23, 2021 04:00PM Phathom Pharmaceuticals to Participate in the 4th Annual Evercore ISI HealthCONx Conference
Nov 23, 2021 04:00PM Phathom Pharmaceuticals to Participate in the 4th Annual Evercore ISI HealthCONx Conference
Nov 12, 2021 04:30PM Phathom Pharmaceuticals to Participate in Two Upcoming Investor Healthcare Conferences
Nov 12, 2021 04:30PM Phathom Pharmaceuticals to Participate in Two Upcoming Investor Healthcare Conferences
Nov 8, 2021 08:00AM Phathom Pharmaceuticals Reports Third Quarter 2021 Results and Provides Key Clinical, Regulatory, and Business Updates
Nov 8, 2021 08:00AM Phathom Pharmaceuticals Reports Third Quarter 2021 Results and Provides Key Clinical, Regulatory, and Business Updates
Oct 25, 2021 05:27AM Phathom Pharmaceuticals Inc. (PHAT) Releases New Data from PHALCON-HP Phase 3 Trial
View More Recent Stories View Older Stories